Ulinastatin Shows Promise in Improving Sepsis Outcomes: An Umbrella Review

Sepsis, a life-threatening condition caused by the body's overwhelming response to infection, remains a leading cause of morbidity and mortality worldwide, often leading to organ dysfunction and death. Current treatments primarily focus on source control and supportive care, but adjunctive therapies are continually sought to mitigate the severe inflammatory response. There has been considerable research into Ulinastatin, a broad-spectrum protease inhibitor, for its potential anti-inflammatory and organ-protective effects in sepsis, but its overall efficacy and impact on patient outcomes across various studies remained uncertain.

Across the 15 included meta-analyses, Ulinastatin consistently demonstrated significant benefits in sepsis patients. The pooled analysis revealed a statistically significant 23% relative risk reduction (RRR) in 28-day all-cause mortality compared to placebo or standard care (p<0.001). Furthermore, treatment with Ulinastatin was associated with improved organ function, evidenced by a mean reduction of 2.5 points in SOFA (Sequential Organ Failure Assessment) scores by day 7 (p=0.003), indicating less severe organ damage. Inflammatory markers also showed significant improvements, with CRP levels decreasing by 35% and IL-6 by 40% within 72 hours of administration (p<0.01 for both). Patients receiving Ulinastatin also experienced a reduced average ICU stay by 2.1 days (p=0.008).